NICE does not recommend ramucirumab (also known as Cyramza and manufactured by Eli Lilly and Company) for people whose stomach cancer has spread or if they have cancer that develops at the point where the food pipe joins to the stomach.
The independent appraisal committee concluded that ramucirumab does not provide enough benefit to patients to justify its high cost and did not qualify for end of life considerations, so it was not recommended.
(29 Jun 2016)
(27 Jun 2016)
(24 Jun 2016)